Communiqués Haemonetics Corporation

Actions

HAE

US4050241003

Equipement, fournitures et distribution médicale

Marché Fermé - NYSE 22:00:02 02/10/2026			Varia. 5j.	Varia. 1 janv.
104,68 ^USD	+0,30 %		-0,59 %	+30,61 %

17/09	L'action Haemonetics progresse après un relèvement de recommandation par Citigroup	MT
17/09	Haemonetics Corporation : Citigroup désormais positif sur le dossier	ZM

Communiqués

30/09	Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026	PR
06/08	Haemonetics: Fiscal Q1 Earnings Snapshot	AQ
06/08	Haemonetics : First Quarter Fiscal 2027 Earnings Release	PU
06/08	Haemonetics : Q1 2027 Haemonetics Corporation Earnings Release	PU
06/08	Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website	PR
03/08	New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths	PR
28/07	Martin Madaus Elected to Haemonetics Board of Directors	PR
08/07	Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026	PR
05/06	Haemonetics Updates Financial Reporting Segments	PR
02/06	Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference	PR
20/05	Haemonetics : Annual Report for Fiscal Year Ending March 28, 2026 (Form 10-K)	PU
07/05	Haemonetics: Fiscal Q4 Earnings Snapshot	AQ
07/05	Haemonetics : 4th Quarter FY26 Earnings Release	PU
07/05	Haemonetics : 4th Quarter FY26 Supplemental Earnings Presentation	PU
07/05	Haemonetics : Q4 2026 Haemonetics Corporation Earnings Release	PU
07/05	Haemonetics : Q4 2026 Analysis Tables & Supplemental Information	PU
07/05	Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website	PR
05/05	Haemonetics to Present at Bank of America 2026 Healthcare Conference	PR
27/04	New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP(R) XL in Large-Bore Venous Access Closure Procedures	AQ
24/04	New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures	PR
01/04	Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026	PR
30/03	Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System	PR
23/02	Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology	PR
20/02	Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference	PR
05/02	Haemonetics: Fiscal Q3 Earnings Snapshot	AQ